Monday - February 23, 2026
Rybrevant Faspro Plus Immunotherapy Shows Strong Clinical Benefit With 56 Percent Overall Response Rate in First-Line Recurrent or Metastatic Head and Neck Cancer
February 20, 2026
RARITAN, New Jersey, Feb. 20 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 19, 2026:

* * *

RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO(TM); results surpass current . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products